poisar

Stocks · News reference

Barclays Maintains Overweight on RadNet, Raises Price Target to $79

BenzingaBenzinga Newsdesk

Barclays analyst Andrew Mok maintains RadNet (NASDAQ:RDNT) with a Overweight and raises the price target from $65 to $79.

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Globenewswire IncDeephealth/Radnet

    New Study Shows DeepHealth AI Could Help Avoid Nearly One in Five Prostate Biopsies

    A multicenter retrospective study published in European Radiology found that combining radiologist assessment with DeepHealth's Prostate AI could reduce unnecessary biopsies by 18.9% while maintaining 98.4% sensitivity in identifying clinically significant prostate cancer. The study analyzed 787 men across Germany, the Netherlands, and the United States, demonstrating vendor-neutral AI performance across diverse imaging equipment.

  2. SEC EDGARSEC EDGAR

    8-K filing — RadNet, Inc. (RDNT)

    Filed: 2026-08-14 AccNo: 0001683168-26-006479 Size: 208 KB Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits